Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bram Verstockt

Showing results (31-40 of 167) with videos related to

Pageof 17
Sort By:
Gastroenterology|January 7, 2022
Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management?Bram Verstockt, Brian Bressler, Helena Martinez-Lozano, et al.
Nature Reviews. Gastroenterology & Hepatology|February 15, 2022
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel diseaseBram Verstockt, Stefania Vetrano, Azucena Salas, et al.
Journal of Gastroenterology and Hepatology|December 28, 2018
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patientsNathalie Van den Berghe, Bram Verstockt, Sophie Tops, et al.
Inflammatory Bowel Diseases|November 9, 2022
Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and OutcomesAn Outtier, Liese Gijbels, Maja Noman, et al.
Inflammatory Bowel Diseases|December 14, 2020
Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network AnalysisPadhmanand Sudhakar, Bram Verstockt, Jonathan Cremer, et al.
Therapeutic Advances in Gastroenterology|September 1, 2023
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's diseaseNathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, et al.
British Journal of Clinical Pharmacology|July 1, 2021
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's diseaseZhigang Wang, Bram Verstockt, João Sabino, et al.
Frontiers in Immunology|November 5, 2021
Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?Inge Jacobs, Matthias Ceulemans, Lucas Wauters, et al.
Journal of Crohn'S & Colitis|February 12, 2022
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for AllPadhmanand Sudhakar, Dahham Alsoud, Judith Wellens, et al.
BMJ Open Gastroenterology|February 6, 2023
Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBDBram Verstockt, Sare Verstockt, Jonathan Cremer, et al.
Pageof 17

Showing results (31-40 of 167) with videos related to

Sort By:
Pageof 17
Gastroenterology|January 7, 2022
Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management?Bram Verstockt, Brian Bressler, Helena Martinez-Lozano, et al.
Nature Reviews. Gastroenterology & Hepatology|February 15, 2022
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel diseaseBram Verstockt, Stefania Vetrano, Azucena Salas, et al.
Journal of Gastroenterology and Hepatology|December 28, 2018
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patientsNathalie Van den Berghe, Bram Verstockt, Sophie Tops, et al.
Inflammatory Bowel Diseases|November 9, 2022
Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and OutcomesAn Outtier, Liese Gijbels, Maja Noman, et al.
Inflammatory Bowel Diseases|December 14, 2020
Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network AnalysisPadhmanand Sudhakar, Bram Verstockt, Jonathan Cremer, et al.
Therapeutic Advances in Gastroenterology|September 1, 2023
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's diseaseNathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, et al.
British Journal of Clinical Pharmacology|July 1, 2021
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's diseaseZhigang Wang, Bram Verstockt, João Sabino, et al.
Frontiers in Immunology|November 5, 2021
Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?Inge Jacobs, Matthias Ceulemans, Lucas Wauters, et al.
Journal of Crohn'S & Colitis|February 12, 2022
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for AllPadhmanand Sudhakar, Dahham Alsoud, Judith Wellens, et al.
BMJ Open Gastroenterology|February 6, 2023
Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBDBram Verstockt, Sare Verstockt, Jonathan Cremer, et al.
Pageof 17